Physician profile
Antonio Prado
NPI 1790783769
$1,417.97
in general payments reported to CMS, 2019-2025
13 companies · $291 in 2025
The $291 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $83.90 · 2021: $59.83 · 2022: $81.85 · 2023: $309 · 2024: $456 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $549.28 | 2020-2025 | Clareon, Argos, Clareon Panoptix Pro |
| Amgen INC. | $172.82 | 2024-2025 | Tepezza |
| Rxsight INC | $149.42 | 2023 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Abbvie INC. | $119.01 | 2023-2025 | |
| Glaukos Corporation | $99.66 | 2024 | Idose |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $87.33 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $69.74 | 2019-2020 | |
| Horizon Therapeutics Plc | $47.93 | 2022-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $32.30 | 2019-2020 | |
| Dompe US, INC. | $29.58 | 2025 | Oxervate |
| Bausch & Lomb Americas INC. | $23.55 | 2022 | |
| Sun Pharmaceutical Industries INC. | $20.26 | 2019 | |
| Allergan, INC. | $17.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Prado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.